PRE.O

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

Retrieved on: 
星期三, 十一月 30, 2022
COVID-19, COVID-19 testing, EBITDA, Colorectal cancer, Genetic testing, Ecosystem, MSCI, Share repurchase, Diagnosis, Environmental impact of pharmaceuticals and personal care products, HK

Following the inclusion of Prenetics, there will be a total of 17 HK-headquartered companies included in this Hong Kong index.

Key Points: 
  • Following the inclusion of Prenetics, there will be a total of 17 HK-headquartered companies included in this Hong Kong index.
  • According to MSCI, the entire MSCI Global Micro Cap index includes a total of 299 constituents in 22 developed markets (with Hong Kong included).
  • It is widely recognised as a benchmark for global institutional investors to optimise their investment portfolios especially passive index funds.
  • In addition, Prenetics' inclusion in the MSCI Global Micro Cap Index (Hong Kong) represents a key milestone and reflects the confidence of stakeholders in the Company's long term growth strategy.

Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance

Retrieved on: 
星期四, 十一月 10, 2022
Ecosystem, Review, Genomics, Genetic testing, Forward-looking statement, Exchange, International Financial Reporting Standards, HSBC, Knowledge, Colorectal cancer, Adjusted gross income, COVID-19 testing, Depreciation, COVID-19, Securities Act of 1933, Holocene, Mission statement, SEC, COVID, NASDAQ, Environmental impact of pharmaceuticals and personal care products, U.S. Securities and Exchange Commission, International, EBITDA, Company, Reconciliation (accounting), Patient, Growth, CEO, Table, Qatar Financial Information Unit, Industry, Diagnosis, Securities Exchange Act of 1934, Tutoring, Bookkeeping, Audit, Security (finance), Operation, Adjustment

Prenetics provides guidance based on current market conditions and expectations for revenue and adjusted EBITDA, which is a non-IFRS financial measure.

Key Points: 
  • Prenetics provides guidance based on current market conditions and expectations for revenue and adjusted EBITDA, which is a non-IFRS financial measure.
  • For full year 2022, Prenetics raises revenue guidance to the range of US$270 million to US$280 million and raises full year adjusted EBITDA guidance to the range of US$47 million to US$53 million.
  • Unaudited Financial Information and Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release.
  • An explanation of these measures is also included below under the heading "Unaudited Financial Information and Non-IFRS Financial Measures."

Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook

Retrieved on: 
星期五, 九月 9, 2022
COVID-19, Securities Act of 1933, EBITDA, Exchange, Qatar Financial Information Unit, Depreciation, IFRS, Table, Adjustment, SEC, Review, U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, Adjusted gross income, International, Company, Ecosystem, Industry, Mission statement, Forward-looking statement, International Financial Reporting Standards, Audit, Security (finance), Operation

See the section titled "Unaudited Financial Information and Non-IFRS Financial Measures" and the table captioned "Reconciliation of (Loss)/Profit from Operations under IFRS and Adjusted EBITDA (Non-IFRS)" for more details.

Key Points: 
  • See the section titled "Unaudited Financial Information and Non-IFRS Financial Measures" and the table captioned "Reconciliation of (Loss)/Profit from Operations under IFRS and Adjusted EBITDA (Non-IFRS)" for more details.
  • Unaudited Financial Information and Non-IFRS Financial Measures has been provided in the financial statements tables included at the end of this press release.
  • An explanation of these measures is also included below under the heading "Unaudited Financial Information and Non-IFRS Financial Measures."
  • Unaudited Financial Information and Non-IFRS Financial Measures
    To supplement Prenetics' consolidated financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), the Company is providing non-IFRS measures, Adjusted EBITDA, adjusted gross profit and adjusted profit for the period.